SENATE BILL 357
J1, J5 5lr2092
CF HB 424
By: Senators Gile and Feldman, Feldman, and Hester
Introduced and read first time: January 16, 2025
Assigned to: Finance
Committee Report: Favorable with amendments
Senate action: Adopted
Read second time: February 22, 2025
CHAPTER ______
1 AN ACT concerning
2 Prescription Drug Affordability Board – Authority for Upper Payment Limits
3 and Stakeholder Council Membership
4 (Lowering Prescription Drug Costs for All Marylanders Now Act)
5 FOR the purpose of altering the membership of the Prescription Drug Affordability
6 Stakeholder Council; requiring the Prescription Drug Affordability Board, under
7 certain circumstances, to establish a process for setting upper payment limits for all
8 purchases and payor reimbursements of prescription drug products in the State that
9 the Board determines have led or will lead to affordability challenges; authorizing
10 the Board to reconsider an upper payment limit for a drug that becomes a current
11 shortage; altering requirements related to the setting of upper payment limits by the
12 Board; requiring the Board to confer with the Maryland Medical Assistance Program
13 before establishing an upper payment limit that applies to the Program; prohibiting
14 the Board from taking certain actions related to upper payment limits; and generally
15 relating to the Prescription Drug Affordability Board.
16 BY repealing and reenacting, with amendments,
17 Article – Health – General
18 Section 21–2C–01, 21–2C–04, 21–2C–13, and 21–2C–14
19 Annotated Code of Maryland
20 (2023 Replacement Volume and 2024 Supplement)
21 BY repealing and reenacting, without amendments,
22 Article – Health – General
23 Section 21–2C–09(c) and 21–2C–11(a)
EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.
[Brackets] indicate matter deleted from existing law.
Underlining indicates amendments to bill.
Strike out indicates matter stricken from the bill by amendment or deleted from the law by
amendment. *sb0357*

2 SENATE BILL 357
1 Annotated Code of Maryland
2 (2023 Replacement Volume and 2024 Supplement)
3 BY adding to
4 Article – Health – General
5 Section 21–2C–09(d) and (e) and 21–2C–16
6 Annotated Code of Maryland
7 (2023 Replacement Volume and 2024 Supplement)
8 BY repealing
9 Article – Health – General
10 Section 21–2C–11(d) and 21–2C–16
11 Annotated Code of Maryland
12 (2023 Replacement Volume and 2024 Supplement)
13 BY adding to
14 Article – Health – General
15 Section 21–2C–16
16 Annotated Code of Maryland
17 (2023 Replacement Volume and 2024 Supplement)
18 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND,
19 That the Laws of Maryland read as follows:
20 Article – Health – General
21 21–2C–01.
22 (a) In this subtitle the following words have the meanings indicated.
23 (b) “Biologic” means a drug that is produced or distributed in accordance with a
24 biologics license application approved under 42 C.F.R. § 447.502.
25 (c) “Biosimilar” means a drug that is produced or distributed in accordance with
26 a biologics license application approved under 42 U.S.C. § 262(k)(3).
27 (d) “Board” means the Prescription Drug Affordability Board.
28 (e) (1) “Brand name drug” means a drug that is produced or distributed in
29 accordance with an original new drug application approved under 21 U.S.C. § 355(c).
30 (2) “Brand name drug” does not include an authorized generic as defined
31 by 42 C.F.R. § 447.502.
32 (F) “CURRENT SHORTAGE” MEANS A DRUG:

SENATE BILL 357 3
1 (1) LISTED AS CURRENT ON THE FEDERAL FOOD AND DRUG
2 ADMINISTRATION’S DRUG SHORTAGE DATABASE; OR
3 (2) OTHERWISE DETERMINED BY THE BOARD TO BE IN SHORT
4 SUPPLY IN THE STATE.
5 [(f)] (G) “Generic drug” means:
6 (1) A retail drug that is marketed or distributed in accordance with an
7 abbreviated new drug application, approved under 21 U.S.C. § 355(j);
8 (2) An authorized generic as defined by 42 C.F.R. § 447.502; or
9 (3) A drug that entered the market before 1962 that was not originally
10 marketed under a new drug application.
11 [(g)] (H) “Manufacturer” means an entity that:
12 (1) (i) Engages in the manufacture of a prescription drug product; or
13 (ii) Enters into a lease with another manufacturer to market and
14 distribute a prescription drug product under the entity’s own name; and
15 (2) Sets or changes the wholesale acquisition cost of the prescription drug
16 product it manufactures or markets.
17 [(h)] (I) “Prescription drug product” means a brand name drug, a generic drug,
18 a biologic, or a biosimilar.
19 [(i)] (J) “Stakeholder Council” means the Prescription Drug Affordability
20 Stakeholder Council.
21 21–2C–04.
22 (a) There is a Prescription Drug Affordability Stakeholder Council.
23 (b) The purpose of the Stakeholder Council is to provide stakeholder input to
24 assist the Board in making decisions as required under this subtitle.
25 (c) (1) The Stakeholder Council consists of [26] members appointed in
26 accordance with this subsection.
27 (2) The Speaker of the House of Delegates shall appoint:
28 (i) One representative of generic drug corporations;

4 SENATE BILL 357
1 (ii) One representative of nonprofit insurance carriers;
2 (iii) One representative of a statewide health care advocacy coalition;
3 (iv) One representative of a statewide advocacy organization for
4 seniors;
5 (v) One representative of a statewide organization for diverse
6 communities;
7 (vi) One representative of a labor union;
8 (vii) ONE REPRESENTATIVE OF THE RARE DISEASE COMMUNITY;
9 (VIII) One health services researcher specializing in prescription
10 drugs; and
11 [(viii)] (IX) One public member at the discretion of the Speaker of the
12 House of Delegates.
13 (3) The President of the Senate shall appoint:
14 (i) One representative of brand name drug corporations;
15 (ii) One representative of physicians;
16 (iii) One representative of nurses;
17 (iv) One representative of hospitals;
18 (v) One representative of dentists;
19 (vi) ONE REPRESENTATIVE OF ONCOLOGISTS;
20 (VII) One representative of managed care organizations;
21 [(vii)] (VIII) One representative of the Department of Budget and
22 Management;
23 [(viii)] (IX) One clinical researcher; and
24 [(ix)] (X) One public member at the discretion of the President of
25 the Senate.
26 (4) The Governor shall appoint:

SENATE BILL 357 5
1 (i) One representative of brand name drug corporations;
2 (ii) One representative of generic drug corporations;
3 (iii) One representative of biotechnology companies;
4 (iv) One representative of for–profit health insurance carriers;
5 (v) One representative of employers;
6 (vi) One representative of pharmacy benefits managers;
7 (vii) One representative of pharmacists;
8 (viii) One pharmacologist; [and]
9 (ix) ONE REPRESENTATIVE OF A PATIENT ADVOCACY
10 ORGANIZATION; AND
11 (X) One public member at the discretion of the Governor.
12 (5) Collectively, the members of the Stakeholder Council shall have
13 knowledge of the following:
14 (i) The pharmaceutical business model;
15 (ii) Supply chain business models;
16 (iii) The practice of medicine or clinical training;
17 (iv) Consumer or patient perspectives;
18 (v) Health care costs trends and drivers;
19 (vi) Clinical and health services research; or
20 (vii) The State’s health care marketplace.
21 (6) To the extent practicable and consistent with federal and State law, the
22 membership of the Stakeholder Council shall reflect the racial, ethnic, and gender diversity
23 of the State.
24 (7) From among the membership of the Stakeholder Council, the Board
25 chair shall appoint two members to be cochairs of the Stakeholder Council.
26 (d) (1) The term of a member is 3 years.

6 SENATE BILL 357
1 (2) The initial members of the Stakeholder Council shall serve staggered
2 terms as required by the terms provided for members on October 1, 2019.
3 (e) A member of the Stakeholder Council:
4 (1) May not receive compensation as a member of the Stakeholder Council;
5 but
6 (2) Is entitled to reimbursement for expenses under the Standard State
7 Travel Regulations, as provided in the State budget.
8 21–2C–09.
9 (c) On or before December 31, 2020, and each December 31 thereafter, the Board
10 shall submit to the Senate Finance Committee and the House Health and Government
11 Operations Committee, in accordance with § 2–1257 of the State Government Article, a
12 report that includes:
13 (1) Price trends for prescription drug products;
14 (2) The number of prescription drug products that were subject to Board
15 review and the results of the review; and
16 (3) Any recommendations the Board may have on further legislation
17 needed to make prescription drug products more affordable in the State.
18 (D) IF THE BOARD SETS A NEW UPPER PAYMENT LIMIT, THE BOARD SHALL
19 INCLUDE IN THE FIRST REPORT THAT IS REQUIRED UNDER SUBSECTION (C) OF THIS
20 SECTION AFTER THE UPPER PAYMENT LIMIT HAS BEEN IN EFFECT FOR 1 YEAR
21 INFORMATION ON THE EFFECTS OF THE UPPER PAYMENT LIMIT, BASED ON
22 AVAILABLE TIMELY DATA, FOR THE FOLLOWING:
23 (1) PATIENT OUT–OF–POCKET COSTS INCLUDING WHETHER THE
24 UPPER PAYMENT LIMIT WAS ASSOCIATED WITH INCREASES OR DECREASES IN WHAT
25 PATIENTS PAY FOR PRESCRIPTION DRUG PRODUCTS;
26 (2) PATIENT HEALTH INSURANCE PREMIUMS, INCLUDING WHETHER
27 THE UPPER PAYMENT LIMIT IS ASSOCIATED WITH INCREASES OR DECREASES IN
28 HEALTH INSURANCE COSTS FOR PATIENTS;
29 (3) PHARMACIES OPERATING IN THE STATE, INCLUDING THE IMPACT
30 ON REIMBURSEMENT RATES AND FINANCIAL VIABILITY OF RETAIL AND
31 INDEPENDENT PHARMACIES;

SENATE BILL 357 7
1 (4) PATIENT HEALTH INSURANCE FORMULARIES, INCLUDING
2 WHETHER THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT
3 LIMIT REMAINED ON FORMULARIES;
4 (5) PROVIDER–ADMINISTERED MEDICATIONS SUBJECT TO THE
5 UPPER PAYMENT LIMIT, INCLUDING WHETHER PROVIDERS WERE ABLE TO ACQUIRE
6 THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER PAYMENT LIMIT AT A
7 RATE TO ACCOUNT FOR ACQUISITION COSTS AND WHETHER THERE WAS AN IMPACT
8 ON PROVIDER REIMBURSEMENT;
9 (6) PATIENT ACCESS TO THE PRESCRIPTION DRUG PRODUCT
10 SUBJECT TO THE UPPER PAYMENT LIMIT, WHICH MAY INCLUDE:
11 (I) WHETHER PRESCRIPTION DRUG PRODUCT SHORTAGES OR
12 OTHER SUPPLY DISRUPTIONS OCCURRED AFTER THE UPPER PAYMENT LIMIT TOOK
13 EFFECT;
14 (II) WHETHER FORMULARY PLACEMENT OR PLAN DESIGN
15 CHANGES MADE THE PRESCRIPTION DRUG PRODUCT SUBJECT TO THE UPPER LIMIT
16 MORE DIFFICULT FOR PATIENTS TO ACCESS, INCLUDING IF INSURANCE PLANS
17 PREFERRED A PRESCRIPTION DRUG PRODUCT WITHOUT AN UPPER PAYMENT LIMIT
18 OVER A PRESCRIPTION DRUG PRODUCT SUBJECT TO AN UPPER PAYMENT LIMIT;
19 (III) WHETHER THE DISTRIBUTION AND DELIVERY OF
20 SPECIALTY OR RARE DISEASE MEDICATIONS FROM OUT–OF–STATE PHARMACIES TO
21 PROVIDERS, PHARMACIES, OR PATIENTS WAS IMPACTED;
22 (IV) WHETHER PATIENTS IN COMMUNITIES OF COLOR,
23 PATIENTS WHO ARE WOMEN, PATIENTS WITH A RARE DISEASE, OR PATIENTS IN
24 RURAL AREAS EXPERIENCED DISPROPORTIONATE ACCESS CHALLENGES; AND
25 (V) WHETHER COST DIFFERENCES AS A RESULT OF THE UPPER
26 PAYMENT LIMIT AFFECTED PATIENTS, PHARMACIES, OR PROVIDERS AND, IF THE
27 COST DIFFERENCE RESULTED IN AN INCREASE IN COSTS, WHO WAS ULTIMATELY
28 RESPONSIBLE FOR BEARING THE INCREASED COST;
29 (7) COVERED ENTITY PROVIDERS PARTICIPATING IN THE 340B DRUG
30 DISCOUNT PROGRAM, INCLUDING THE IMPACT OF THE UPPER PAYMENT LIMIT ON
31 THE OPERATIONS OF THE PROVIDERS AND THEIR CONTRACTED PHARMACIES; AND
32 (8) THE BIOTECHNOLOGY INDUSTRY IN THE STATE, INCLUDING THE
33 IMPACT ON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, INVESTMENT, AND
34 JOB GROWTH.

8 SENATE BILL 357
1 (E) (1) THE BOARD MAY REQUEST INFORMATION NECESSARY TO
2 COMPLETE THE REPORT REQUIRED UNDER SUBSECTIONS (C) AND (D) OF THIS
3 SECTION FROM AN AFFECTED ENTITY.
4 (2) THE ENTITY FROM WHICH INFORMATION WAS REQUESTED UNDER
5 PARAGRAPH (1) OF THIS SUBSECTION SHALL MAKE A GOOD FAITH EFFORT TO
6 PROVIDE THE REQUESTED INFORMATION.
7 21–2C–11.
8 (a) In this section, “Fund” means the Prescription Drug Affordability Fund.
9 [(d) (1) The Board shall be established using special or general funds, which
10 shall be repaid to the State with the funds from the Fund.
11 (2) If the Board receives funding from the Maryland Health Care
12 Commission under paragraph (1) of this subsection, the Board shall repay the funds to the
13 Commission from the Fund over a 3–year period beginning June 1, 2021.]
14 21–2C–13.
15 (a) If, under § 21–2C–07 of this subtitle, the Board finds that it is in the best
16 interest of the State to establish a process for setting upper payment limits for prescription
17 drug products that it determines have led or will lead to an affordability challenge, the
18 Board, in conjunction with the Stakeholder Council, shall draft a plan of action for
19 implementing the process [that includes the criteria the Board shall use to set upper
20 payment limits] IN ACCORDANCE WITH THE REQUIREMENTS OF THIS SECTION.
21 (b) The criteria for setting upper payment limits shall include consideration of:
22 (1) The cost of administering the prescription drug product;
23 (2) The cost of delivering the prescription drug product to consumers; [and]
24 (3) THE EFFECT THE UPPER PAYMENT LIMIT WILL HAVE ON
25 PROVIDERS OF 340B DRUGS;
26 (4) FOR AN UPPER PAYMENT LIMIT ON A DRUG THAT IS DESIGNATED
27 AS A DRUG FOR A RARE DISEASE OR CONDITION, THE IMPACT OF THE UPPER
28 PAYMENT LIMIT ON PATIENTS WITH RARE DISEASES; AND
29 [(3)] (4) (5) Other relevant administrative costs related to the prescription
30 drug product.
31 [(c) The process for setting upper payment limits shall:

SENATE BILL 357 9
1 (1) Prohibit the application of an upper payment limit for a prescription
2 drug product that is on the federal Food and Drug Administration prescription drug
3 shortage list; and
4 (2) Require the Board to:
5 (i) Monitor the availability of any prescription drug product for
6 which it sets an upper payment limit; and
7 (ii) If there becomes a shortage of the prescription drug product in
8 the State, reconsider or suspend the upper payment limit.]
9 (C) (1) IF THE BOARD PREVIOUSLY SET AN UPPER PAYMENT LIMIT FOR A
10 DRUG THAT BECOMES A CURRENT SHORTAGE, THE BOARD MAY RECONSIDER THE
11 PREVIOUSLY SET UPPER PAYMENT LIMIT.
12 (2) THE BOARD MAY NOT:
13 (I) ESTABLISH A NEW UPPER PAYMENT LIMIT FOR A CURRENT
14 SHORTAGE;
15 (II) ENFORCE AN UPPER PAYMENT LIMIT AGAINST PROVIDER
16 OR PHARMACY REIMBURSEMENT REQUIREMENTS FOR MEDICARE PART C OR PART
17 D PLANS; OR
18 (III) COUNT A PHARMACY DISPENSING FEE TOWARD OR
19 SUBJECT A PHARMACY DISPENSING FEE TO AN UPPER PAYMENT LIMIT.
20 (d) (1) If a plan of action is drafted under subsection (a) of this section, the
21 Board shall submit the plan of action to the Legislative Policy Committee of the General
22 Assembly, in accordance with § 2–1257 of the State Government Article, for its approval.
23 (2) The Legislative Policy Committee shall have 45 days to approve the
24 plan of action.
25 (3) If the Legislative Policy Committee does not approve the plan of action,
26 the Board shall submit the plan to the Governor and the Attorney General for approval.
27 (4) The Governor and the Attorney General shall have 45 days to approve
28 the plan of action.
29 (5) The Board may not set upper payment limits unless the plan is
30 approved, in accordance with this subsection, by:
31 (i) The Legislative Policy Committee; or

10 SENATE BILL 357
1 (ii) 1. The Governor; and
2 2. The Attorney General.
3 21–2C–14.
4 [(a) If a plan of action is approved under § 21–2C–13(d) of this subtitle] IN
5 ACCORDANCE WITH THE PLAN OF ACTION APPROVED BY THE LEGISLATIVE POLICY
6 COMMITTEE ON OCTOBER 22, 2024, the Board may set upper payment limits for
7 prescription drug products that are:
8 (1) Purchased or paid for by a unit of State or local government or an
9 organization on behalf of a unit of State or local government, including:
10 (i) State or county correctional facilities;
11 (ii) State hospitals; and
12 (iii) Health clinics at State institutions of higher education;
13 (2) Paid for through a health benefit plan on behalf of a unit of State or
14 local government, including a county, bicounty, or municipal employee health benefit plan;
15 or
16 (3) Purchased for or paid for by the Maryland State Medical Assistance
17 Program.
18 [(b) The upper payment limits set under subsection (a) of this section shall:
19 (1) Be for prescription drug products that have led or will lead to an
20 affordability challenge; and
21 (2) Be set in accordance with the criteria established in regulations
22 adopted by the Board.
23 (c) (1) The Board shall:
24 (i) Monitor the availability of any prescription drug product for
25 which it sets an upper payment limit; and
26 (ii) If there becomes a shortage of the prescription drug product in
27 the State, reconsider whether the upper payment limit should be suspended or altered.

SENATE BILL 357 11
1 (2) An upper payment limit set under subsection (a) of this section may not
2 be applied to a prescription drug product while the prescription drug product is on the
3 federal Food and Drug Administration prescription drug shortage list.]
4 [21–2C–16.
5 On or before December 1, 2026, the Board, in consultation with the Stakeholder
6 Council, shall report to the Senate Finance Committee and the House Health and
7 Government Operations Committee, in accordance with § 2–1257 of the State Government
8 Article, on:
9 (1) The legality, obstacles, and benefits of setting upper payment limits on
10 all purchases and payor reimbursements of prescription drug products in the State; and
11 (2) Recommendations regarding whether the General Assembly should
12 pass legislation to expand the authority of the Board to set upper payment limits to all
13 purchases and payor reimbursements of prescription drug products in the State.]
14 21–2C–16.
15 (A) (1) THE BOARD, IN CONSULTATION WITH THE STAKEHOLDER
16 COUNCIL, SHALL DETERMINE WHETHER, IN ADDITION TO SETTING UPPER PAYMENT
17 LIMITS IN ACCORDANCE WITH § 21–2C–14 OF THIS SUBTITLE, IT IS IN THE BEST
18 INTEREST OF THE STATE FOR THE BOARD TO ESTABLISH A PROCESS FOR SETTING
19 UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
20 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
21 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
22 (2) WHEN MAKING A DETERMINATION UNDER PARAGRAPH (1) OF
23 THIS SUBSECTION, THE BOARD SHALL CONSIDER, IF APPLICABLE:
24 (I) CONTRACT AND BUDGET DATA PROVIDED TO THE BOARD
25 THAT DEMONSTRATES SAVINGS TO THE STATE OR LOCAL GOVERNMENTS AS A
26 RESULT OF UPPER PAYMENT LIMITS SET IN ACCORDANCE WITH § 21–2C–14 OF THIS
27 SUBTITLE;
28 (II) SUCCESS OF SETTING UPPER PAYMENT LIMITS IN OTHER
29 STATES; AND
30 (III) EXPECTED SAVINGS FROM MEDICARE MAXIMUM FAIR
31 PRICES SET BY THE CENTERS FOR MEDICARE AND MEDICAID SERVICES.
32 (B) (1) IF THE BOARD MAKES AN AFFIRMATIVE DETERMINATION UNDER
33 SUBSECTION (A) OF THIS SECTION, THE BOARD, IN CONSULTATION WITH THE

12 SENATE BILL 357
1 STAKEHOLDER COUNCIL, SHALL ESTABLISH A PROCESS FOR SETTING UPPER
2 PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR REIMBURSEMENTS OF
3 PRESCRIPTION DRUG PRODUCTS IN THE STATE THAT THE BOARD DETERMINES
4 HAVE LED OR WILL LEAD TO AN AFFORDABILITY CHALLENGE.
5 (2) THE PROCESS ESTABLISHED UNDER PARAGRAPH (1) OF THIS
6 SUBSECTION SHALL:
7 (I) TO THE EXTENT APPROPRIATE, USE THE PLAN OF ACTION
8 APPROVED UNDER § 21–2C–13(D) OF THIS SUBTITLE; AND
9 (II) OTHERWISE COMPLY WITH THE REQUIREMENTS FOR
10 SETTING UPPER PAYMENT LIMITS ESTABLISHED UNDER THIS SUBTITLE.
11 (3) BEFORE ESTABLISHING AN UPPER PAYMENT LIMIT THAT APPLIES
12 TO THE MARYLAND MEDICAL ASSISTANCE PROGRAM, THE BOARD SHALL CONFER
13 WITH THE MARYLAND MEDICAL ASSISTANCE PROGRAM TO APPROVE THE
14 APPLICATION OF THE UPPER PAYMENT LIMIT BY ASSESSING WHETHER THE
15 PROPOSED UPPER PAYMENT LIMIT WILL:
16 (I) CONFLICT WITH THE MEDICAID DRUG REBATES
17 PROGRAM, THE COVERED OUTPATIENT DRUG RULE (CMS–2345–FC), OR ANY
18 OTHER FEDERAL REQUIREMENTS AS APPLICABLE; AND
19 (II) REQUIRE ADDITIONAL FUNDING TO BE ALLOCATED TO THE
20 MARYLAND MEDICAL ASSISTANCE PROGRAM BUDGET.
21 SECTION 2. AND BE IT FURTHER ENACTED, That the Laws of Maryland read
22 as follows:
23 Article – Health – General
24 21–2C–16.
25 (C) (1) IF SUBJECT TO PARAGRAPH (2) OF THIS SUBSECTION, IF THE
26 BOARD ESTABLISHES A PROCESS UNDER SUBSECTION (B) OF THIS SECTION, THE
27 BOARD SHALL SET UPPER PAYMENT LIMITS FOR ALL PURCHASES AND PAYOR
28 REIMBURSEMENTS OF PRESCRIPTION DRUG PRODUCTS IN THE STATE IN
29 ACCORDANCE WITH THE PROCESS.
30 (2) THIS SUBSECTION DOES NOT APPLY WITH RESPECT TO:
31 (I) PAYOR REIMBURSEMENTS UNDER MEDICARE PART C AND
32 D PLANS;

SENATE BILL 357 13
1 (II) PURCHASES UNDER THE FEDERAL 340B DRUG PRICING
2 PROGRAM; AND
3 (III) PURCHASES AND PAYOR REIMBURSEMENTS UNDER
4 FEDERAL PROGRAMS THAT ARE PREEMPTED BY FEDERAL LAW INCLUDING:
5 1. THE DEPARTMENT OF DEFENSE;
6 2. THE DEPARTMENT OF VETERANS AFFAIRS;
7 3. THE PUBLIC HEALTH SERVICE;
8 4. THE UNITED STATES COAST GUARD;
9 5. TRICARE;
10 6. THE FEDERAL EMPLOYEES HEALTH BENEFIT PLAN;
11 AND
12 7. ANY OTHER EXCLUSIVE FEDERAL PROGRAM AS
13 APPLICABLE.
14 SECTION 3. AND BE IT FURTHER ENACTED, That:
15 (a) Section 2 of this Act is contingent on the Prescription Drug Affordability Board
16 setting upper payment limits on two prescription drugs in accordance with § 21–2C–14 of
17 the Health – General Article, as enacted by Section 1 of this Act, and each upper payment
18 limit being in effect for 1 year.
19 (b) Within 5 days after the conditions described in subsection (a) of this section
20 are met, the Prescription Drug Affordability Board shall notify the Department of
21 Legislative Services.
22 (c) If notice is received by the Department of Legislative Services in accordance
23 with subsection (b) of this section on or before September 31 September 30, 2030, Section 2
24 of this Act shall take effect on the date the notice is received by the Department of
25 Legislative Services.
26 (d) If notice is not received by the Department of Legislative Services on or before
27 December 31 September 30, 2030, Section 2 of this Act, with no further action required by
28 the General Assembly, shall be null and void.
29 SECTION 4. AND BE IT FURTHER ENACTED, That, subject to Section 3 of this
30 Act, this Act shall take effect October 1, 2025.

[DELETED: :CA      5   C A P a ( F t p o a t m o t P D A S C r t P D A B u c p t t s B b t r B  A S  A  ( B  A S]
[DELETED:  S   A  ( B  A  S  A  ( B  A S  A  ( B  A S  A  (  S T A 2  ( I  ( “ b  ( “ a  ( “  ( ( “ a   ( “ b ) “C”:UE ]
[DELETED: S 3   LF A C O T F O A R’DSD;NS R H AE    O D B T O T B I S T.  () “](   ( A a   ( A   ( A m  () “](   ( ( E    ( E d   ( S p  () “]( a  () “ C m t P D A]( S 2  ( T  ( T a  ( ( T S C c o 26 m a i a   ( T    ( O]
[DELETED:  S     ( O    ( O    ( O r o a s a o f s    ( O r o a s o f d c    ( O    ( ;    () h s r s i p d    () () O H   ( T    ( O    ( O    ( O    ( O    ( O    (      O    ()  r o t D o B a](V M    ()  O](    () O]( t   ( T]
[DELETED: S 5    ( O    ( O    ( O    ( O    ( O    ( O    ( O    ( O ad    ( R O A P AN       O   ( C t m o t S C s h k    ( T    ( S    ( T    ( C    ( H    ( C    ( T   ( T m o   ( F c  ( ( T]
[DELETED:  S    ( T t  ( A   ( M b   ( I T 2  ( O s O r   ( P   ( T r   ( A r t B m h o f l n  )IB,F OT  O C  A T U P L H B I E F  Y O T E O T U P LT B OA     )P– OTOFP C I W T    )PS  U P L I A W I O D I    )PS TE  R R A F V O R A ]
[DELETED: S 7   )P H I FS I    )PRA M S T TT     ) A T T P D PT      )H     )IH F P O P D D F P T AS I I I P     )IH T D A D OTOFSS S ,     )WVH P I C O CR W A WN P W A R DE O P IS      )HS S D ,S     )C3  M S     )TS TE T T  ]
[DELETED:  S    )()TH O M R I N T T R R U S C A D O T)(    )  O T S S M A G F E TN 2  ( I ( ( T s   ( I t B r f f t M H C C C 2  ( I i d B i c w t S C s d a p o a f i t pst i t c t B s u t s u ps.  ( T   ( T   ( T;a] (  E T U P L W H O  B; (  A D F A R D O CN T I O T US  []()( ()O d ( T]
[DELETED: S 9   ( P d p t i o t f F a D A p d s   ( R    ( M t a o a p d p f w    ( I t() ( IF OE  O ( TB: O  () SE  () IN E A   APC;S   () IO A P D F T O  ( ( I B A   ( T p   ( I t   ( T t   ( T B m n s u p l u t p i a    ( T]
[DELETED:  S     ( 1 T     2 T 2  ( I a p o a i a u § 2 o t se] E OO2,2 O C  , t B m s u p l f p   ( P o p f b a u o S o l g o a o    ( S    ( S    ( H   ( P l o   ( P P  ( T   ( B f p d p t h l o w l t a a   ( B s i a w t c e i r a  ( ( T    ( M t a o a p d p f w    ( I t]
[DELETED: S 1   ( A b f. 2  O C s r t t S F C a t H H a G A   ( T a   ( R r w t G A s p p() ( TB,H OD I C W T T,L R    E 24 T O D P I T T T T O D ( W( M A D U P  ON  OR B,:  () CO O D S T T T O L G A A   2  () IUS   () EMMIX S F E A ACMMS. E E E E() ( IF O A O T SN T OD I C W T),B]
[DELETED:  S C OL S E A P F S U L F A P A P R O D P I T T T T O D ( T( P E U P  O T  () TOE   D E 2();  () IT C W T R F (  A E S RM  OMAP, T A E S R T A TMA O T U P L B A W T  () CMDO W T E R E,CODR(M T O U R U  O AE   () IEMAP. E S RT  S a A 2() ( IS()F U T P  O T SN I T() B N  S S U P L F A P A P O P D P I T T IS ( T:  () PMPA E A  P;L]
[DELETED: S 1  () P3BDIU U T F  R R;M   () IU A P R U   1 TDD; E E   2 TDVA; E E F   3 TPHS; U E E   4 TUSCG; N T O U   5 T;   6 TFEHBP E M E E LN   7  O E F P A    S  ( S s t l  ( W a m t P D A B s n t D o L  ( I w o t A s t e o t d t n i r b t D o L  ( I D t  S A]